Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

PD-1 Inhibitor Cemiplimab Active in B-Lymphoid Malignancies

December 11th 2017

Cemiplimab as a monotherapy and in combination with the monoclonal antibody REGN1979 demonstrated clinical activity in patients with B-cell non-Hodgkin lymphoma and Hodgkin lymphoma.

Axi-Cel Responses Sustained With Longer Follow-Up for NHL

December 10th 2017

Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.

Tisagenlecleucel Continues to Impress in DLBCL

December 10th 2017

The CAR T-cell therapy tisagenlecleucel (Kymriah) achieved an overall response rate of 53.1% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Zanubrutinib Highly Active in Non-Hodgkin Lymphoma

December 10th 2017

The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.

What You Need to Know: Hematologic Malignancies

December 6th 2017

Q & A Session for Hematologic Malignancies

December 6th 2017

MRD Testing in Hematologic Malignancies

December 6th 2017

Phase III Data for Relapsed/Refractory Myeloma

December 6th 2017

Key Studies in Newly-Diagnosed Multiple Myeloma

December 6th 2017

Daratumumab for Smoldering Myeloma

December 6th 2017

KRd for High-Risk Smoldering Myeloma

December 6th 2017

AML Studies: BiTE Antibodies and Age for Transplant

December 6th 2017

AML Studies: FLT3 Inhibitors

December 6th 2017

Acute Myeloid Leukemia: Novel Targeted Therapies

December 6th 2017

NHL Studies: CAR T Therapy, Rituximab Maintenance, & PD-L1

December 6th 2017

New Data for Mantle Cell Lymphoma

December 6th 2017

Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVD

December 6th 2017

Pre-Conference Perspectives on Hematologic Malignancies

December 6th 2017

Ibrutinib Combo Improves PFS in Waldenstrom Macroglobulinemia

December 6th 2017

The combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) improved progression-free survival versus rituximab alone in patients with Waldenström macroglobulinemia.

Expert Emphasizes Appropriate Diagnosis, Staging of T-Cell Lymphomas

December 1st 2017

Sunita D. Nasta, MD, compares the biology of peripheral and cutaneous T-cell lymphomas and offered advice on the optimal therapeutic approaches for either disease with novel agents.